Abstract | OBJECTIVE: ANIMALS: 11 dogs with PDH. PROCEDURE: The initial dose of trilostane was 30 mg, PO, q 24 h for dogs that weighed < 5 kg and 60 mg, PO, q 24 h for dogs that weighed > or = 5 kg. A CBC count, serum biochemical analyses, urinalysis, ACTH stimulation test, and ultrasonographic evaluation of the adrenal glands were performed in each dog 1, 3 to 4, 6 to 7, 12 to 16, and 24 to 28 weeks after initiation of treatment. RESULTS: All dogs responded well to treatment. All had reductions in polyuria- polydipsia and panting and an increase in activity. Polyphagia decreased in 9 of 10 dogs, and 9 of 11 dogs had improvement of coat quality and skin condition. Concentration of cortisol after ACTH stimulation significantly decreased by 1 week after initiation of treatment. After treatment for 6 months, clinical signs resolved in 9 dogs. In the other 2 dogs, marked clinical improvement was reported for 1 dog, and moderate improvement was reported in the other dog. Ultrasonographically, there was a considerable change in the parenchyma and an increase in size of the adrenal glands. Adverse effects consisted of 1 dog with transient lethargy and 1 dog with anorexia. CONCLUSIONS AND CLINICAL RELEVANCE:
Trilostane is an efficacious and safe medication for treatment of dogs with PDH. Additional studies in a larger group of dogs and characterization of progressive changes in adrenal glands are needed.
|
Authors | Nadja S Ruckstuhl, Claudia S Nett, Claudia E Reusch |
Journal | American journal of veterinary research
(Am J Vet Res)
Vol. 63
Issue 4
Pg. 506-12
(Apr 2002)
ISSN: 0002-9645 [Print] United States |
PMID | 11939311
(Publication Type: Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Dihydrotestosterone
- Adrenocorticotropic Hormone
- trilostane
- Hydrocortisone
|
Topics |
- Adrenocortical Hyperfunction
(blood, diagnostic imaging, drug therapy, veterinary)
- Adrenocorticotropic Hormone
(administration & dosage)
- Animals
- Blood Cell Count
(veterinary)
- Blood Chemical Analysis
(veterinary)
- Dihydrotestosterone
(adverse effects, analogs & derivatives, therapeutic use)
- Dog Diseases
(blood, diagnostic imaging, drug therapy)
- Dogs
- Enzyme Inhibitors
(adverse effects, therapeutic use)
- Female
- Hydrocortisone
(blood)
- Male
- Pituitary Diseases
(blood, diagnostic imaging, drug therapy, veterinary)
- Polyuria
(drug therapy, veterinary)
- Prospective Studies
- Ultrasonography
|